{"product_id":"cjc-1295-ipamorelin-cjc-ipa","title":"CJC-1295 \/ Ipamorelin (CJC\/IPA)","description":"\u003cp dir=\"ltr\"\u003e\u003cspan\u003eA combination of two growth hormone secretagogues studied for complementary mechanisms. CJC-1295 extends GH (Growth Hormone) release duration while ipamorelin triggers targeted GH pulses.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eWhat Is CJC\/Ipamorelin?\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCJC-1295\/Ipamorelin combines two growth hormone secretagogues that work through distinct pathways. CJC-1295 is a modified GHRH analog with an extended half-life, designed to sustain elevated GH levels over longer periods. Ipamorelin is a selective GHS-R agonist that stimulates GH release in a pulsatile pattern without significantly affecting cortisol or prolactin levels.\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 dir=\"ltr\"\u003e\u003cspan\u003eHistory\u003c\/span\u003e\u003c\/h3\u003e\n\u003cp dir=\"ltr\"\u003e\u003cspan\u003eCJC-1295 was developed by ConjuChem Biotechnologies in the early 2000s as a long-acting GHRH analog. Its extended half-life results from modifications that increase albumin binding. Ipamorelin was first characterized in the late 1990s by Novo Nordisk researchers, who identified it as one of the most selective growth hormone secretagogues available. The practice of combining the two compounds emerged from clinical research settings where investigators sought to optimize both the amplitude and duration of GH release.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"Protocol Aminos","offers":[{"title":"10MG","offer_id":44807980154925,"sku":null,"price":89.0,"currency_code":"COP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0744\/2232\/1197\/files\/CJC_IPA.png?v=1775604391","url":"https:\/\/protocolaminos.com\/products\/cjc-1295-ipamorelin-cjc-ipa","provider":"Protocol Aminos","version":"1.0","type":"link"}